PMID- 30271212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: 
      a systematic review and meta-analysis.
PG  - 3637-3648
LID - 10.2147/CMAR.S168610 [doi]
AB  - BACKGROUND: Lenalidomide is effective for the treatment of low-risk 
      myelodysplastic syndromes with deletion 5q abnormalities. However, whether 
      lenalidomide leads to a significant improvement in treatment response and overall 
      survival (OS) in cases of acute myeloid leukemia (AML) remains controversial. A 
      systematic review and a meta-analysis were performed to evaluate the efficacy and 
      safety of lenalidomide in the treatment of AML. METHODS: Clinical studies were 
      identified from the Cochrane Central Register of Controlled Trials, PubMed, 
      Embase, and ClinicalTrials.gov. Efficacy outcomes included overall response rate 
      (ORR), complete remission (CR), and OS. Safety was evaluated based on the 
      incidence of grade 3 and 4 treatment-related adverse events (AEs). RESULTS: 
      Eleven studies were included in our meta-analysis; collectively these studies 
      featured 407 AML patients. Pooled estimates for overall ORR and CR were 31% (95% 
      CI: 26%-36%) and 21% (95% CI: 16%-27%), respectively. Thrombocytopenia, anemia, 
      neutropenia, and infection were the most common grade 3 and 4 AEs. CONCLUSION: 
      Lenalidomide may have some clinical activity in AML, but the population that 
      would benefit from lenalidomide and incorporating lenalidomide into combination 
      drug strategies need to be better defined.
FAU - Xie, Chun-Hong
AU  - Xie CH
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Wei, Min
AU  - Wei M
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Yang, Fei-Yan
AU  - Yang FY
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Wu, Fu-Zhen
AU  - Wu FZ
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Chen, Lei
AU  - Chen L
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Wang, Jian-Kun
AU  - Wang JK
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Liu, Qin
AU  - Liu Q
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
FAU - Huang, Jin-Xiong
AU  - Huang JX
AD  - Department of Hematology, Affiliated Liuzhou People's Hospital of Guangxi 
      University of Science and Technology (Liuzhou People's Hospital), Liuzhou 545000, 
      Guangxi, China, lzrmyyhjx@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180918
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6152603
OTO - NOTNLM
OT  - azacitidine
OT  - cytarabine
OT  - cytogenetic risk
OT  - immunomodulatory agent
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/10/03 06:00
MHDA- 2018/10/03 06:01
PMCR- 2018/09/18
CRDT- 2018/10/02 06:00
PHST- 2018/10/02 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2018/10/03 06:01 [medline]
PHST- 2018/09/18 00:00 [pmc-release]
AID - cmar-10-3637 [pii]
AID - 10.2147/CMAR.S168610 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Sep 18;10:3637-3648. doi: 10.2147/CMAR.S168610. 
      eCollection 2018.